One in Medical Technology

CTMM Becomes One of the World's Largest Public-Private Partnerships in Translational Medical Research

EINDHOVEN, The Netherlands, August 4 /PRNewswire/ -- With today's final approval of a research project into prostate cancer, the Dutch CTMM (Center for Translational Molecular Medicine) today announced the successful completion of 265 million euro funding for translational (bench-to-bedside) m...

IMPACT Study Showed Longer Valcyte(R) (valganciclovir hydrochloride tablets) Treatment Demonstrated Better Protection Against Cytomegalovirus (CMV) Disease One Year Post-Transplant

CMV is the most serious viral infection affecting transplant patients BOSTON, June 1 /PRNewswire/ -- New Phase III study results presented for the first time today at the ninth annual American Transplant Congress 2009 (ATC) demonstrate that doubling the duration of preventive therapy ('prop...

Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results

First-Ever Trial to Evaluate Whether Olmesartan Medoxomil Prevents Onset of Early Kidney Disease in Type 2 Diabetes Patients SAN FRANCISCO, May 8 /PRNewswire/ -- Blinded one-year blood pressure (BP) reduction data from the ongoing landmark study ROADMAP ( R andomized O lmesartan A nd D ...

China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit

HARBIN, China, May 4 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI ), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that the R...

Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009

NEW HAVEN, Conn., April 2 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced that its lead compound, delafloxacin, ha...

Pain Relief in Just One Visit with Genzyme's Synvisc-One

Single-injection products will drive the US Hyaluronic Acid Viscosupplementation market to nearly $1 billion by 2013, according to Millennium Research Group WALTHAM, Mass., March 23 /PRNewswire/ -- According to Millennium Research Group's (MRG's) US Markets for Orthopedic Biomaterials 2009 ...

American Oriental Bioengineering to Initiate a Phase One Clinical Trial in the United States of AOBO-001 Oral Capsule

NEW YORK, March 9 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB ), a China-based pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") pr...

Staying One Step Ahead of Osteoporosis

New studies show key steps to preventing bone loss focus on early screening and treatment LAS VEGAS, Feb. 26 /PRNewswire-USNewswire/ -- Facts about osteoporosis are staggering. 75 million baby boomers are approaching the age where the disease is tightening its grip on their bones. ...

Laser Burn Injuries in One Eye Can Disrupt Protective Immune Privilege in Both Eyes, Study Finds

Findings have implications for treating returning vets and others exposed to laser burns BOSTON, Feb. 26 /PRNewswire-USNewswire/ -- Scientists at Schepens Eye Research Institute have shown for the first time that a laser burn to one retina can cause both eyes to lose a special protective abil...

Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection

SCOTTSDALE, Ariz., Feb. 10 /PRNewswire/ -- Recent clinical data show that Restylane (R) lasted 18 months in 97% of patients with one repeat injection. Restylane (R) is the only HA filler with an 18-month FDA-approved duration claim. These data were generated in a controlled, randomiz...

RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments

- After eight weeks of treatment, RAD001 halted tumor growth in 55% of advanced gastric cancer patients previously treated with chemotherapy - Based on these promising data, Novartis will initiate a Phase III trial of RAD001 for advanced gastric cancer patients - Gastric cancer is the s...

Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD

In a clinical study of adults, VYVANSE taken once-daily significantly improved the symptoms of ADHD within one week PHILADELPHIA, Oct. 7 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that a study published in th...

China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials

HARBIN, China, Sept. 10 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Amex: CSY ), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that it s...

New Research Shows One in 200 People Born with DNA Mutation That Can Lead to Devastating, Often Fatal Disease

Mutation Causing Mitochondrial Disease More Common Than Previously Believed PITTSBURGH, Aug. 11 /PRNewswire-USNewswire/ -- The United Mitochondrial Disease Foundation (UMDF) today announced landmark research finding that one in every 200 people has a DNA mutation that could potentially cause...

CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year

-Study shows angina at one year associated with significantly higher incidence of depression- PALO ALTO, Calif., June 23 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX ) today announced that the Archives of Internal Medicine published results of a major...

After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008

Phase 3 Once Weekly Investigational Diabetes Therapy Also Improved Glucose Control in Patients Switching from Exenatide Taken Twice a Day SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ), and Alkermes, Inc. (N...

Dr. Peter Nash, Ph.D. Joins Mach One Corporation as Chief Scientist

Leading Developer of Antibody Technologies to Strengthen Management Team WEST BEND, Wis., April 30 /PRNewswire-FirstCall/ -- Mach One Corporation (Pink sheets: MNCN), a manufacturer and distributor of products for animal health, announced today the appointment of Dr. Peter C. Nash, Ph.D. as Ch...

Medivation's Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimer's Disease Patients Over One Year

- Cognitive Function Data from Pivotal Trial Presented at American Academy of Neurology 60th Annual Meeting - SAN FRANCISCO and CHICAGO, April 17 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN ) today announced that Alzheimer's patients treated with the investigatio...

Supportive Oncology Services Accrues One Million Cancer Patient Self-Reported Assessments

Direct Collection of Patient-Reported Outcomes (PROs) Improves Cancer Care MEMPHIS, Tenn., April 14 /PRNewswire/ -- Supportive Oncology Services, Inc. (SOS), a noted leader in oncology research-based health information, announced today it has accrued over one million cancer patient self-reporte...

The Yolanda Adams Morning Show and Radio One Gospel Stations Raise More Than $1 Million During National Radiothon Benefiting St. Jude

First-ever Radio One/St. Jude Radiothon reached listeners in nine cities across the United States MEMPHIS, Tenn., April 10 /PRNewswire-USNewswire/ -- The Yolanda Adams Morning Show and nine Radio One gospel radio stations raised $1,015,773 during the first-ever Radio One/St. Jude Radi...

Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market

VIENNA, Austria, April 7 /PRNewswire/ -- A biosimilar product for treating the negative effects that cancer chemotherapy can have on the white blood cells of patients is safe and exhibits an identical pharmacokinetic and pharmacodynamic profile compared to a reference product. This is the resu...

NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society

Data Analysis Shows Promise of Epiretinal Brachytherapy as NeoVista Progresses with Phase III CABERNET Study PALM BEACH, Fla., March 28 /PRNewswire/ -- NeoVista, Inc. released today to the eye community updated results from a one-year feasibility study of the company's novel e...

Carpet One Floor & Home Continues Making Dramatic Strides in Funding Breast Cancer Research and Awareness

MANCHESTER, N.H., March 24 /PRNewswire/ -- Now in its fourth year, Carpet One Floor & Home once again rolls out the welcome mats for breast cancer research and awareness with the Spring 2008 Carpet One Floor & Home Welcomes Your Support Campaign. Store locations throughout North America contin...

Huge Drop in Preterm Birth-Risk Among Women Taking Folic Acid One Year Before Conception

Largest U.S. Study of Pre-conceptional Folic Acid Supplementation Receives March of Dimes Award DALLAS, Jan. 31 /PRNewswire-USNewswire/ -- New research suggests that women who take folic acid supplements for at least one year before they become pregnant can cut their risk of having a prema...

Breast Cancer Treatment Is Reduced to One Week

Chicago-Area Community Hospital to Offer New Clinical Study to Breast Cancer Patients EVERGREEN PARK, Ill., Jan. 29 /PRNewswire/ -- Little Company of Mary Hospital and Health Care Centers in Evergreen Park, Illinois, near Chicago ( http://www.PursuingPainFreeCancer....

Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes

Doctors Are Combining Portrait(R) Plasma with Fractionated Lasers Or in Place of Surgery to Alleviate the Signs of Aging of the Eyes WALTHAM, Mass., Jan. 24 /PRNewswire/ -- When it comes to the aging eye area, going under the knife is no longer the only option. According to the American A...

Video: New Results From One of the World's Largest Breast Cancer Trials Herald Hope for Thousands of Women

Benefits of Arimidex (anastrozole) over tamoxifen at preventing all forms of breast cancer recurrence increase over time - even four years after treatment ends SAN ANTONIO, Dec. 14 /PRNewswire/ -- New data from ATAC*, one of the world's largest and longest-running...

CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year

Two Large Phase III Trials Confirm Robust Efficacy of CIMZIA BOSTON, Nov. 7 /PRNewswire/ -- UCB announced today the results of new Phase III data from the RAPID 1 and 2 studies presented at the American College of Rheumatology Annual Scientific Meeting (ACR), which show CIMZIA(R) (certol...

Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year

DALLAS, Nov. 1 /PRNewswire-USNewswire/ -- Death resulting from influenza, often referred to as "the flu," is more common among individuals with heart disease than among patients with any other chronic medical condition. However, according to a new nationwide survey of heart disease patients co...

Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors

BOULDER, Colo. and MONTREAL, Oct. 10 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM ) and MethylGene Inc. (TSX: MYG) today announced the initiation of a Phase One clinical trial evaluating MGCD0103, the Companies' isotype-selective histone deacetylase inhibitor (HDACi) product c...

WaveSense Blood Glucose Meter One of Few Brands to Pass Rigorous TNO Tests

SALEM, N.H., Oct. 9 /PRNewswire/ -- The Wellion Linus Blood Glucose Monitoring System, powered by WaveSense technology for high accuracy testing, recently received certification by the Netherlands Organization for Applied Scientific Research TNO ("TNO"). TNO is an independent group founded in ...

UCB Announces Positive Top-Line Phase III Results for Keppra as Adjunctive Therapy for Partial Onset Seizures in Paediatric Patients from One Month to Less than Four Years of Age

UCB Announces Positive Top-Line Phase III Results for Keppra® as Adjunctive Therapy for Partial Onset Seizures in Paediatric Patients from One Month to Less than Four Years of Age BRUSSELS, Belgium - April 20, 2007 - UCB today announced positive top-line results from a phase III, double-blin...

NuPathe Reports Positive Phase One Results for NP101 Transdermal Therapy for Acute Migraine

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Jun 8, 2007 - NuPathe Inc., a privately held specialty pharmaceutical company, today announced positive results from an initial Phase I study of NP101 SmartRelief, a novel treatment for acute migraine being developed by NuPathe. NP101 combines NuPathe's SmartRel...

Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent

Results Highlighted in Oral Presentation at International Symposium of Thrombosis and Haemostasis GENEVA, July 10, 2007 /PRNewswire-FirstCall/ -- Baxter Healthcare Corporation today announced the presentation of findings from the ADAPT (Analysis of Data from ADVATE(R) Prospective Trials) study pro...

Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases

...hemotherapy for retinoblastoma, a cancer affecting one in 15,000 children, must now be given intravenousl...ded in 1928 with 12,000 members currently, ARVO is one of the nation's largest organizations for research...tric and adolescent health. Children's Hospital is one of America's premier teaching hospitals, affiliate...

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

...novative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing saf.... Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a mat...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...2 diabetes Begin clinical trials on at least one additional drug in 2009; clinical trials already i...ast two additional drugs into development in 2009; one new drug has already moved into development this y...e and six months ended June 30, 2008 only included one month of amortization of the $175 million license ...

Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership

...e Genomics Institute of the Novartis Research Foundation (GNF) to create a diabetes drug discovery and development platform. The four-year program is one of the largest and most comprehensive collaborations in the 40 year history of JDRF, a leader in setting the agenda for diabetes research worldwide an...

Cancer Centers of North Carolina Offers HDR Brachytherapy for Treatment of Cancerous Tumors

...Centers of North Carolina's office, which incorporates all patient needs in one central location. In addition, treatment times for HDR brachytherapy are t...gs the best of medical science and cancer care support services together in one pleasant, convenient, community- based organization. For more information, ...

SIRO Clinpharm Completes Successful Implementation of Oracle Life Sciences Application Suite

...ns. About SIRO SIRO Clinpharm Private Limited (SIRO) is among one of the leading global Clinical Research Organizations (CROs), offering full...medical devices sectors in compliance with international standards. SIRO is one of the first CROs founded in India, which caters to the needs of pharmaceut...